Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 5/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479105 | 0.92 | RAF1 (0.46) | KDRDDR2RAF1RETBRAF | |
| SCHEMBL9103895 | 0.89 | KDR (0.37) | KDRDDR2GRM5CCNCCDK8 | |
| SCHEMBL4473374 | 0.88 | DDR2 (0.54) | KDRDDR2GRM5RAF1RET | |
| SCHEMBL4476005 | 0.82 | RAF1 (0.45) | KDRDDR2RAF1RETBRAF | |
| SCHEMBL4485725 | 0.82 | RET (0.50) | KDRDDR2GRM5RAF1RET | |
| SCHEMBL4485728 | 0.81 | RET (0.43) | KDRDDR2GRM5RAF1RET | |
| SCHEMBL4463605 | 0.80 | LMNA (0.46) | KDRDDR2RAF1RETBRAF | |
| SCHEMBL4474065 | 0.80 | DDR2 (0.55) | KDRDDR2RAF1RETBRAF | |
| SCHEMBL4463621 | 0.80 | RET (0.55) | KDRDDR2GRM5RAF1RET | |
| SCHEMBL4467857 | 0.78 | RET (0.51) | KDRDDR2GRM5RAF1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685125-B1 | Pyrrole derivatives useful for the treatment of proliferative diseases | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | claimed |
| US-20070149594-A1 | Pyrrole derivatives | MERCK PATENT GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| US-7598274-B2 | N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20070149594-A1 | Pyrrole derivatives | MERCK PATENT GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149594-A1 | Pyrrole derivatives | RAF1, BRAF, ARAF | KDR 2076/4885DDR2 3148/4885GRM5 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.